Braunschweig, I <br/><br/>
High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer.  [electronic resource] 

 -  Cytotherapy  2000 
 - 105-10 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>1465-3249 
<br/><br/><label>Standard No.: </label>10.1080/146532400539107  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antigens, CD34--metabolism<br/>Blood Component Removal<br/>Blood Transfusion, Autologous--adverse effects<br/>Breast Neoplasms--blood<br/>Female<br/>Hematopoietic Stem Cell Mobilization<br/>Hematopoietic Stem Cell Transplantation--adverse effects<br/>Humans<br/>Middle Aged<br/>Survival Rate<br/>Time Factors<br/>Treatment Outcome